Propentofylline (Synonyms: HOE 285, HWA 285) |
Katalog-Nr.GC46208
One-Click Copy Product Info
|
Propentofyllin ist ein Xanthin-Derivat, das die Aufnahme von Adenosin hemmt und die Phosphodiesterase-AktivitÄt blockiert.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 55242-55-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Propentofylline is a xanthine derivative and neuroprotective agent.1,2 It increases NGF production in primary mouse astroglia when used at concentrations ranging from 0.12 to 3.33 mM, with the maximum increase observed at 1.11 mM.1 Propentofylline (20 μg/ml) reduces cell death induced by amyloid-β (1-42) in primary rat hippocampal neurons.2 Intravenous infusion of propentofylline (0.01, 0.05, and 0.1 mg/kg per minute) reduces infarct volume in a rat model of ischemic brain damage induced by permanent middle cerebral artery occlusion (MCAO) when administered following MCAO.3 It inhibits cAMP phosphodiesterases, is an antagonist of adenosine A1 and A2 receptors, and binds to adenosine transporters.4,5
|1. Shinoda, I., Furukawa, Y., and Furukawa, S. Stimulation of nerve growth factor synthesis/secretion by propentofylline in cultured mouse astroglial cells. Biochem. Pharmacol. 39(11), 1813-1816 (1990).|2. Koriyama, Y., Chiba, K., and Mohri, T. Propentofylline protects β-amyloid protein-induced apoptosis in cultured rat hippocampal neurons. Eur. J. Pharmacol. 458(3), 235-241 (2003).|3. Park, C.K., and Rudolphi, K.A. Antiischemic effects of propentofylline (HWA 285) against focal cerebral infarction in rats. Neurosci. Lett. 178(2), 235-238 (1994).|4. Nagata, K., Ogawa, T., Omosu, M., et al. In vitro and in vivo inhibitory effects of propentofylline on cyclic AMP phosphodiesterase activity. Arzneimittelforschung 35(7), 1034-1036 (1985).|5. Fredholm, B.B., Fastbom, J., Kvanta, A., et al. Further evidence that propentofylline (HWA 285) influences both adenosine receptors and adenosine transport. Fundam. Clin. Pharmacol. 6(3), 99-111 (1992).
| Cas No. | 55242-55-2 | SDF | |
| Überlieferungen | HOE 285, HWA 285 | ||
| Canonical SMILES | CCCN(C=N1)C2=C1N(C)C(N(CCCCC(C)=O)C2=O)=O | ||
| Formula | C15H22N4O3 | M.Wt | 306.4 |
| Löslichkeit | Acetonitrile: slightly soluble,Chloroform: slightly soluble | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.2637 mL | 16.3185 mL | 32.6371 mL |
| 5 mM | 652.7 μL | 3.2637 mL | 6.5274 mL |
| 10 mM | 326.4 μL | 1.6319 mL | 3.2637 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 33 reference(s) in Google Scholar.)